Tropolone Derivatives in Cancer Therapeutics

Tropolone derivatives, characterised by their seven-membered aromatic ring and accessible hydroxyl group, have emerged as versatile agents in oncology. Natural congeners such as hinokitiol exhibit multifaceted activity, including induction of programmed cell death, modulation of autophagy and inhibition of metastatic processes. Synthetic analogues, notably α-substituted tropolones, exploit metal-chelation to interfere with metalloenzyme function, including selective histone deacetylases, thereby altering epigenetic regulation in tumour cells. Across diverse malignancies—from breast and lung carcinomas to osteosarcoma and multiple myeloma—these compounds trigger cell-cycle arrest, enhance reactive oxygen species signalling and suppress cancer stem-cell renewal. Advances in formulation and pharmacokinetic profiling have begun to address challenges of bioavailability and off-target toxicity, paving the way for clinical translation. Collectively, tropolone chemistry bridges natural product heritage and rational design, offering a global platform for next-generation cancer therapeutics with potential to overcome resistance and limit adverse effects.

Research from Nature Portfolio

A recent chemical synthesis study described a one-pot route to fluorescent cyclic-aminotroponiminium carboxylate derivatives displaying DNA-binding affinity without classical intercalation. In vitro and in vivo evaluations of selected derivatives showed potent inhibition of cervical carcinoma proliferation and migration, mediated by p38-p53-dependent apoptosis and suppression of epithelial–mesenchymal transition. Intrinsic fluorescence enabled subcellular tracking, confirming nuclear and cytoplasmic localisation. In xenograft models, these molecules markedly reduced tumour growth with minimal systemic toxicity, highlighting the promise of tailored tropolone frameworks for targeted cancer therapy.

Tropolone Derivatives in Cancer Therapeutics publication trend

The graph below shows the total number of articles in tropolone derivatives in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Tropolone: A seven-membered non-benzenoid aromatic compound bearing a hydroxyl group, capable of metal chelation and enzyme inhibition.

Apoptosis: Programmed cell death characterised by caspase activation, DNA fragmentation and membrane blebbing.

Autophagy: A catabolic process in which cells degrade and recycle cytoplasmic components via lysosomal pathways.

Histone deacetylase (HDAC): Enzymes that remove acetyl groups from histone proteins, modulating chromatin structure and gene expression.

Epithelium–mesenchymal transition (EMT): A reversible process by which epithelial cells acquire mesenchymal traits, enhancing migratory and invasive potential.

Xenograft: A transplantation model in which human tumour cells are implanted into immunocompromised animals to study in vivo drug efficacy.

References

1. One-pot synthesis of cyclic-aminotropiminium carboxylate derivatives with DNA binding and anticancer properties. Communications Chemistry (2022).
2. Hinokitiol Inhibits Breast Cancer Cells In Vitro Stemness-Progression and Self-Renewal with Apoptosis and Autophagy Modulation via the CD44/Nanog/SOX2/Oct4 Pathway. International Journal of Molecular Sciences (2024).
3. Development and Validation of an LC-MS/MS Assay for the Quantitation of MO-OH-Nap Tropolone in Mouse Plasma: Application to In Vitro and In Vivo Pharmacokinetic Studies. Molecules (2024).
4. Different Cell Responses to Hinokitiol Treatment Result in Senescence or Apoptosis in Human Osteosarcoma Cell Lines. International Journal of Molecular Sciences (2022).